Level Bio (LEVBIO) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 increased by 5% year-over-year to 6,750 KSEK, with a strengthened gross margin of 57% compared to 52% last year.

• Net result after tax improved to -164 KSEK from -889 KSEK year-over-year, and operating result was -207 KSEK, impacted by 528 KSEK in goodwill and amortization from the Cybergene acquisition.

• Positive cash flow of 16 KSEK in Q3 2025, compared to -621 KSEK in Q3 2024.

• Subsidiary Techtum Lab secured a significant order worth approximately 1.5 MSEK for a single-cell analysis instrument, with delivery expected in H1 2026.

Financial highlights

• Gross profit for Q3 2025 was 3,787 KSEK, up from 3,330 KSEK in Q3 2024.

• Cash and cash equivalents at the end of Q3 2025 were 1,574 KSEK, up from 1,342 KSEK a year earlier.

• Equity per share at period end was 0.03 SEK, down from 0.08 SEK in Q3 2024.

• Market capitalization at period end was 23.3 MSEK, compared to 26.7 MSEK last year.

Outlook and guidance

• Q4 2025 started strongly, with sales already surpassing the full year 2024 by the time of report publication.

• Focus remains on organic sales growth, expanding in the Nordics, and leveraging a strong product portfolio in diagnostics.